PMID- 19142796
OWN - NLM
STAT- MEDLINE
DCOM- 20090304
LR  - 20211020
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 50
IP  - 1
DP  - 2009 Jan
TI  - Allogeneic stem cell transplantation with alemtuzumab-based conditioning for 
      patients with advanced chronic myelogenous leukemia.
PG  - 85-91
LID - 10.1080/10428190802626624 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment 
      of choice for patients with chronic myelogenous leukemia (CML) who have failed or 
      are intolerant to tyrosine kinase inhibitors (TKI). Myeloablative conditioning 
      regimens have been associated with high treatment-related mortality (TRM) rate in 
      such patients, and reduced-intensity conditioning (RIC) regimens are often 
      preferred but have high rates of disease recurrence and graft-versus-host-disease 
      (GVHD). We report our experience with nine CML patients (four chronic phase and 
      five with accelerated phase or blast crisis) who failed TKI and underwent 
      allo-HSCT using an alemtuzumab-based RIC regimen. The conditioning regimen was 
      well tolerated and induced engraftment in all patients, and complete cytogenetic 
      remission (CCyR) in eight of nine. Four patients, all with a history of 
      accelerated phase or blast crisis, died. Four of the five remaining patients had 
      a cytogenetic relapse a median of 10 months after transplantation. Donor 
      lymphocyte infusion (DLI), TKI or both induced a CCyR in all cases. With a median 
      follow-up of 47 months, five patients, including all those transplanted in first 
      or second chronic phase, are alive and in remission. Allo-HSCT with an 
      alemtuzumab-based conditioning regimen induces remission in patients with CML 
      that have failed TKI therapy and has a low incidence of GVHD. Disease recurrence 
      is frequent but responds to DLI. In some cases, restoration of susceptibility to 
      TKI was observed. Outcomes may improve with the routine administration of 
      post-transplant TKI.
FAU - Poire, Xavier
AU  - Poire X
AD  - Section of Hematology/Oncology, Department of Medicine and the Cancer Research 
      Center, The University of Chicago, Chicago, IL 60637, USA.
FAU - Artz, Andrew
AU  - Artz A
FAU - Larson, Richard A
AU  - Larson RA
FAU - Kline, Justin
AU  - Kline J
FAU - Odenike, Olatoyosi
AU  - Odenike O
FAU - Rich, Elizabeth
AU  - Rich E
FAU - Godley, Lucy
AU  - Godley L
FAU - Stock, Wendy
AU  - Stock W
FAU - van Besien, Koen
AU  - van Besien K
LA  - eng
GR  - K24 CA116471/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antibodies, Neoplasm)
RN  - 3A189DH42V (Alemtuzumab)
SB  - IM
MH  - Adult
MH  - Alemtuzumab
MH  - Antibodies, Monoclonal/*immunology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antibodies, Neoplasm/*immunology/*therapeutic use
MH  - Combined Modality Therapy
MH  - Female
MH  - Graft vs Host Disease/immunology
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Immunotherapy
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug 
      therapy/*immunology/pathology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Survival Rate
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
PMC - PMC3617055
MID - NIHMS452872
EDAT- 2009/01/15 09:00
MHDA- 2009/03/05 09:00
PMCR- 2013/04/04
CRDT- 2009/01/15 09:00
PHST- 2009/01/15 09:00 [entrez]
PHST- 2009/01/15 09:00 [pubmed]
PHST- 2009/03/05 09:00 [medline]
PHST- 2013/04/04 00:00 [pmc-release]
AID - 907774745 [pii]
AID - 10.1080/10428190802626624 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2009 Jan;50(1):85-91. doi: 10.1080/10428190802626624.